Haematological as well as biochemical parameters assessing anaemia associating protein energy malnutrition PEM were estimated. Data revealed that controls studied have a relatively lower Hb, Ht, and R.B.C.S. count than European standards. Hypochromic anaemia was predominant in 83.3% of moderate Kwashiorkor being normocytic in 50% and microcytic in 33.3%. In severe KWO anaemia was normocytic in 42% and microcytic in 19.2%. Normochromia was found in 9.7% and hypochromia in 29%. Macrocytosis was found in 38.8% in severe KWO. In marasmus, normocytic anaemia was revealed in 74% of the 2nd. grade being normochromic in 82% and hypochromic in 40%. Macrocytic anaemia was detected in 26%. In 3rd. grade subjects normocytic normochromic anaemia occurred in 70% of the cases. Macrocytosis was encountered among 30% of the cases. Serum iron and transferrin level dropped in both KWO and marasmus, the extent of decrease was greater in the former. The percent transferrin saturation was elevated in severe cases. Particularly severe KWO and marasmic KWO.
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Update on the treatment navigation for functional cure of chronic hepatitis B: expert consensus 2.0.
Clin Mol Hepatol
January 2025
Department of Infectious Diseases, Tongji Hospital, Tongji Medical College and State Key Laboratory for Diagnosis and Treatment of Severe Zoonotic Infectious Disease, Huazhong University of Science and Technology, Wuhan, China.
As new evidence emerges, treatment strategies toward the functional cure of chronic hepatitis B are evolving. In 2019, a panel of national hepatologists published a Consensus Statement on the functional cure of chronic hepatitis B. Currently, an international group of hepatologists has been assembled to evaluate research since the publication of the original consensus, and to collaboratively develop the updated statements.
View Article and Find Full Text PDFPatient-reported assessment of medical care for chronic inflammatory skin diseases: an enterprise-based survey.
Front Med (Lausanne)
April 2024
Psoriasis Research and Treatment Center, Charité - Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany.
Background: Chronic inflammatory skin diseases (CISDs) are among the most common diseases in the Western world. Current estimates of medical care for CISDs are primarily based on surveys among patients in medical care facilities and on health insurance data.
Aim: Survey-based examination to what extent CISD patients in health-aware environment consider their skin disease to be controlled.
Viral Hepatitis and Acute-on-Chronic Liver Failure.
Clin Liver Dis
August 2023
Stanford University School of Medicine, Palo Alto, CA, USA. Electronic address:
Acute-on-chronic liver failure (ACLF) is a potentially reversible syndrome that develops in patients with cirrhosis or with underlying chronic liver disease (CLD) and is characterized by acute decompensation, organ failure, and high short-term mortality. Hepatitis A and hepatitis E are major causes of ACLF. Hepatitis B may also cause ACLF through a flare of hepatitis B, acute infection, or reactivation.
View Article and Find Full Text PDFImpact of COVID-19 on Liver Transplant Activity in the USA: Variation by Etiology and Cirrhosis Complications.
J Clin Transl Hepatol
February 2023
University of South Dakota Sanford, School of Medicine, Vermillion, SD, USA.
Background And Aims: The COVID-19 pandemic has impacted the care of patients with liver disease. We examined impact of COVID-19 on liver transplant (LT) activity in the USA.
Methods: LT listings in the United Network for Organ Sharing (UNOS) database (April 2018-May 2021) were analyzed to examine the impact of COVID-19 pandemic on the LT activity based on etiology: hepatitis C virus (HCV), alcohol-associated liver disease (ALD), alcoholic hepatitis (AH), and nonalcoholic steatohepatitis (NASH) complications: hepatocellular carcinoma (HCC) and acute-on-chronic liver failure (ACLF) grade 2 or 3) and Model for End-Stage Liver Disease (MELD) score.
Mortality in patients with end-stage liver disease above model for end-stage liver disease 3.0 of 40.
Hepatology
March 2023
Division of Gastroenterology and Hepatology, Department of Medicine , Stanford University School of Medicine, Redwood City , California , USA.
Background And Aims: Since the implementation of the model for end-stage liver disease (MELD) score to determine waitlist priority for liver transplant (LT) in 2002, the score has been capped at 40. Recently, the MELD 3.0 score was proposed to improve upon MELD-Na.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!